Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective […]

Related Keywords

United States , Piper Sandler , Brian Joseph Lynch , York Mellon Corp , Madrigal Pharmaceuticals Stock Down , Madrigal Pharmaceuticals Inc , Analyst Recommendations For Madrigal Pharmaceuticals , Boxer Capital , Wintrust Investments , Nasdaq , Deutsche Bank , Insider Activity At Madrigal Pharmaceuticals , Securities Exchange Commission , Madrigal Pharmaceuticals , News Ratings For Madrigal Pharmaceuticals Daily , Jp Morgan Private Wealth Advisors , Get Free Report , Marketbeat Ratings , Joseph Lynch , Exchange Commission , Advisors Lp Baker , New York Mellon Corp , Private Wealth Advisors , Pharmaceuticals Stock Down , Get Free , Madrigal Pharmaceuticals Daily , Nasdaq Mdgl , Mdgl , Medical , 87162t20 , Ratings , Consensus ,